- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00431665
Effect of Elevated Plasma-Free-Fatty-Acids on Renal Hemodynamic Parameters
Type 2 diabetes is frequently associated with elevation of plasma-free fatty acids (FFA). Studies indicate that elevation of plasma-FFA induces insulin resistance and also causes endothelial dysfunction as well as hemodynamic changes which are supposed to be involved in the pathogenesis of diabetic vascular disorders.
Glomerular hyperfiltration, which is associated with glomerular hypertension and hypertrophy, a common finding in the early course of type 1 diabetes as well as type 2 diabetes, plays an important role in the development and progression of diabetic nephropathy. These hemodynamic changes are not well understood, but are most likely induced by dilatation of the (precapillary) glomerular arteriole.
In humans the hemodynamic effect of FFAs has so far been investigated locally in brachial and femoral arteries and recently in the eye and skin, where FFAs induced a pronounced increase in blood flow probably due to a local decrease in vascular resistance.
The aim of the present study is to characterise the hemodynamic effects of FFAs in the kidney. In addition we want to test the hypothesis that FFA-induced changes are mediated via endothelial derived nitric oxide (NO). The results of this study could provide information to what extent elevated FFA-plasma levels contribute to hyperfiltration in the early course of diabetes mellitus. The measurements will be done at baseline and during 4 hour infusion of a triglyceride or placebo infusion, combined with heparin.
Study Overview
Status
Conditions
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Department of Clinical Pharmacology, Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men aged between 19 and 35 years
- Body mass index between 15th and 85th percentile (Must et al. 1991)
- Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
Exclusion Criteria:
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Evidence of hypertension, pathologic hyperglycemia, hyperlipidemia
- Treatment in the previous 3 weeks with any drug
- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
- History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Glomerular filtration rate
|
Renal plasma flow
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Roden, MD, Department of Internal Medicine III, Medical University of Vienna
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anticoagulants
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Fat Emulsions, Intravenous
- Heparin
- Soybean oil, phospholipid emulsion
- Somatostatin
- omega-N-Methylarginine
Other Study ID Numbers
- OPHT-070699
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glomerular Filtration Rate
-
University Health Network, TorontoCompletedGlomerular Filtration Rate | Renal Blood FlowCanada
-
Paris Translational Research Center for Organ TransplantationCompletedKidney Transplantation | Glomerular Filtration RateUnited States, Croatia, France, Italy
-
The University of Texas Health Science Center,...Not yet recruitingAnemia | Decreased Glomerular Filtration RateUnited States
-
First Affiliated Hospital of Jinan UniversityUnknownGlomerular Filtration Rate | Bariatric SurgeryChina
-
AstraZenecaIqvia Pty LtdCompletedPrediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate From Digital Retinal ImagesKenya
-
MediBeaconCompletedAcute Kidney Injury | Glomerular Filtration RateUnited States
-
MediBeaconCompletedAcute Kidney Injury | Glomerular Filtration RateUnited States
-
Temple UniversityWyeth is now a wholly owned subsidiary of PfizerUnknownGlomerular Filtration Rate | Chronic Allograft NephropathyUnited States
-
Azienda Socio Sanitaria Territoriale degli Spedali...UnknownGlomerular Filtration Rate | Nephrectomy | Kidney NeoplasmItaly
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; University Medical Center Groningen and other collaboratorsUnknownKidney Transplantation | Acute Kidney Injury | Glomerular Filtration Rate | Delayed Graft FunctionNetherlands, Denmark, Sweden
Clinical Trials on heparin
-
San Filippo Neri General HospitalUniversity of Roma La SapienzaUnknownAngina, Unstable | Stable Angina | Non-ST Elevation (NSTEMI) Myocardial InfarctionItaly
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownRenal Failure | HemodialysisItaly
-
Azidus BrasilUnknownPrevention of Venous ThromboembolismBrazil
-
Robert F. JamesIndiana University School of MedicineSuspendedNeurobehavioral Manifestations | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, Intracranial | Intracranial Aneurysm | Heparin-induced Thrombocytopenia Type IIUnited States
-
Regado Biosciences, Inc.CompletedAcute Coronary Syndrome (ACS)United States, Canada, Germany, France
-
University of OklahomaRecruitingRecurrent Urinary Tract InfectionsUnited States
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); Australian and New Zealand Intensive... and other collaboratorsCompletedCritical Illness | Deep Venous ThrombosisUnited States, Australia, Canada, Saudi Arabia, Brazil, United Kingdom
-
Christine RibicMcMaster University; LEO PharmaCompleted
-
University of UtahCompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary EmbolismUnited States